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Effects of Ex Vivo SkinMicrobiopsy
onHistopathologic Diagnosis
inMelanocytic Skin Lesions
Currently,histopathologicanalysis represents thepractical ref-
erence standard for the diagnosis of melanocytic skin le-
sions.However, thereare limitationsparticularly related to the
morphologic nature of thehistopathologic interpretation and
the influenceof theclinical informationon the finaldiagnosis.1
Toprovide lesional tissue frommelanocytic proliferations for
molecular analysiswithout jeopardizing the conventional his-
topathologicdiagnosis,we inventedaminiaturizedbiopsyde-
vicewith a totalwidthof 0.35mm, containing a sample cham-
ber 0.15 mmwide. This device penetrates approximately 250
μm in healthy skin (ie, superficial dermis) to collect approxi-
mately 1600 cells.2 Thismicrobiopsydevice canbeusedwith-
out local anesthetic, and there is noneed for a suture. Our hy-
pothesis is that the minimal skin damage caused by the
microbiopsy does not interfere with the subsequent histo-
pathologic diagnosis.
Methods |Fivepatients scheduled for suspiciouspigmented le-
sion removal at the dermatology department of the Princess
AlexandraHospital, a public tertiaryhospital inBrisbane,Aus-
tralia, were recruited. Con-
sent was obtained from all
participants with approval
from The University of
Queensland/PrincessAlexandraHospitalHumanResearchEth-
ics Committees. Clinical images of the lesions were taken be-
fore surgery and immediately after excision. Each excised le-
sionwasbisected, and 5microbiopsy specimenswere applied
ex vivo to one of the halved lesions. The microbiopsy site lo-
cationsweredocumented, and the specimenswere labeledac-
cordingly. All specimens were sectioned in the hospital’s pa-
thology laboratory according to routine protocol.
Results | All sections were examined by a dermatopathologist
(D.L.) for the histopathologic diagnosis, with special empha-
sis on the microbiopsy defect. The mean (SD) size of the mi-
crobiopsy defect was 113 (50) μm wide and 146 (37) μm deep
(n = 4). These defects are comparable, albeit not identical, to
processing artifacts in nonmicrobiopsied specimens ranging
from 20 to 2100 μmwide and 70 to 600μmdeep. Histopatho-
logicdiagnoses inbothhalves,whileexaminedseparately,were
exactly the same in all lesions. Diagnoses included com-
pound nevus, junctional lentiginous nevus, compound dys-
plastic nevus, junctional dysplastic nevus, and solar lentigo.
From the 5 lesions included in the study, 2 are displayed
herein clinically and histopathologically. Patient 1 was an 88-
year-oldmanwith ahistoryofmetastaticmelanoma,whohad
adeepshaveexcisionofanewnevus identifiedonhis left flank.
One of themicrobiopsy defects identifiedwithin themelano-
cytic region was 132 × 74 μm in size (Figure 1). The diagnosis
was a compound dysplastic nevus. Patient 2 was a 56-year-
oldwomanwithhistoryofnonmelanomaskincancer,whopre-
sented with a changing nevus on her left scapula. One of the
microbiopsy defects found outside the lesional region was
145 × 201μmand reached the superficial dermis (Figure 2). Di-
agnosis of this lesion was junctional lentiginous nevus.
Discussion |Over theyears,manymicrodeviceshavebeendevel-
opedtoobtain tissuesamples,3-5 but interestinglyenoughnone
ofthesemicrodevicesarespecificallyengineeredforskinlesions.
Becauseof thenewexcitingdevelopmentsof targetedmolecu-
lar therapies in patients withmelanoma,6 there is a need for a
minimally invasivebiopsydevice enabling small tissue collec-
tionwithminimal adverseeffects toperformdownstreammo-
lecular diagnosis ofmelanocytic skin lesions.
Thesizeofmicrobiopsydefectsmeasured in this studywas
comparable to other artifacts more or less commonly seen in
routine sectioned specimens. The potential diagnostic diffi-
culties for the dermatopathologist encountered with the his-
topathologic assessment of amicrobiopsiedmelanocytic skin
lesion can easily be overcome by orderingmultiple levels. All
5 melanocytic lesions included in this study were not diffi-
cult to assess, and therefore the diagnostic process was not
hamperedby themicrobiopsy-induced artifacts; however, on
the basis of the size of the microbiopsy artifacts, we foresee
that the diagnostic process, even in equivocal cases, will not
be influenced. The data from this study support the hypoth-
esis thatminimal skindamagecausedby themicrobiopsydoes
not affect the histopathologic diagnosis.
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Figure 1. Patient 1
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A, Patient 1 clinical photograph;
B, excised lesions; and C, microbiopsy
sites (white arrows). D, The
microbiopsy device with a sample;
E, the site of microbiopsy at low
magnification; and F, the site at high
magnification.
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Figure 2. Patient 2
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A, Patient 2 clinical photograph;
B, excised lesions; and C, microbiopsy
sites (white arrows). D, The
microbiopsy site at low
magnification; and E, the site at high
magnification.
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